Get started
Work

106P Immunotherapy after progression to double immunotherapy: Pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition

Year: 2024
Type: article
Abstract: PD-1 inhibition as monotherapy following by CTLA-4 inhibition at progression or as upfront double co-inhibition have drastically improved the outcomes of metastatic melanoma. Still many patients develop resistance to both ICIs and relapse soon, having conventional chemotherapy(CC) as the only therapeutic option. The phase II LEAP-004 trial supported that pembrolizumab/lenvatinib could potentially overcome anti-PD-1/anti-CTLA-4 immunotherapy refractoriness.
DOI: 10.1016/j.iotech.2024.100849
Authors: D. Ziogas, G. Lyrarakis, M. Liontos, A. Anastasopoulou, S. Bouros, A. Gkoufa, P. Diamantopoulos, H. Gogas
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
Estimated APC paid: $3,170
OpenAlex ID: W4405375253
FWCI:
Cites:
Cited by:
Related to: 10